Encoded Therapeutics, Inc.

Encoded Therapeutics, Inc. is a biotechnology company focused on developing genetic medicines for central nervous system disorders, utilizing innovative gene therapies to address significant health challenges. Encoded Therapeutics was founded in 2014 and is headquartered in South San Francisco, US. The company specializes in creating gene therapies for CNS disorders.

The founders, Kartik Ramamoorthi and Stephanie Tagliatela, have backgrounds in biotechnology and pharmaceuticals. The company has completed four funding deals, with the most recent being a Series D round on July 22, 2020, raising USD 125 mn led by GV and included participation from other investors. The total amount raised by the company to date is USD 125 mn, with a current valuation of USD 540. 86 mn.

Encoded Therapeutics specializes in developing genetic medicines aimed at addressing central nervous system (CNS) disorders, which contribute significantly to global morbidity and mortality. The company's core product offerings include novel gene therapies designed to target specific cell types with unique genetic profiles, enhancing specificity, selectivity, and potency compared to earlier therapies. Their flagship product, ETX101, targets Dravet Syndrome, a severe epilepsy form, aiming to provide long-lasting benefits for patients. Encoded Therapeutics collaborates with healthcare professionals, hospitals, and research institutions across North America and Europe.

Encoded Therapeutics generates revenue through partnerships with healthcare institutions and pharmaceutical companies seeking innovative CNS therapies. Their B2B model includes collaborations with research organizations and hospitals for clinical trials and product development, which may involve licensing agreements that provide access to proprietary technologies. While specific pricing structures are not disclosed, the company likely uses value-based pricing models reflecting potential health benefits and cost savings from their advanced gene therapies. As clinical stages progress toward commercialization, these revenue channels are expected to expand significantly.

Encoded Therapeutics aims to leverage the USD 125 mn raised during the Series D funding round to advance its pipeline of gene therapies, focusing on the clinical development of ETX101 and potentially other products targeting CNS disorders. The company is exploring expansion into additional markets in North America and Europe by 2023, targeting healthcare systems that require innovative treatments for complex health challenges. The funding will be instrumental in supporting ongoing clinical trials and accelerating product development initiatives.